Stay updated on ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:35:07.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the clinical trial data related to the treatment of soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, and small cell lung cancer. This change reflects an update in the metabolic reprogramming induced by ADI-PEG20, gemcitabine, and docetaxel combination therapy, potentially impacting the clinical benefit rate and treatment outcomes for patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:21.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    38%
    Check dated 2024-05-22T20:32:51.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:44:52.000Z thumbnail image

Stay in the know with updates to ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page.